Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Hiroshi Kitoh"'
Autor:
Itaru Kawashima, Masaki Matsushita, Kenichi Mishima, Yasunari Kamiya, Yusuke Osawa, Bisei Ohkawara, Kinji Ohno, Hiroshi Kitoh, Shiro Imagama
Publikováno v:
BMC Musculoskeletal Disorders, Vol 24, Iss 1, Pp 1-10 (2023)
Abstract Background Postmenopausal osteoporosis is a widespread health concern due to its prevalence among older adults and an associated high risk of fracture. The downregulation of bone regeneration delays fracture healing. Activated fibroblast gro
Externí odkaz:
https://doaj.org/article/5799846324ae40b599c9115aa3054e4e
Autor:
Kenichi Mishima, Yuka Tsukagoshi Okabe, Masaaki Mizuno, Kinji Ohno, Hiroshi Kitoh, Shiro Imagama
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract The proton pump inhibitor lansoprazole has been previously identified to upregulate the expression and transcriptional activity of runt-related transcription factor 2 (Runx2) that promotes lineage commitment and differentiation of osteoproge
Externí odkaz:
https://doaj.org/article/24926c8eb6d540858f0466cbaa2f2998
Autor:
Hiroshi Kitoh, Masako Izawa, Hiroshi Kaneko, Akiko Kitamura, Saori Matsuyama, Kohji Kato, Tomoo Ogi
Publikováno v:
Bone Reports, Vol 17, Iss , Pp 101626- (2022)
Hypophosphatasia (HPP), a genetic disorder characterized by decreased tissue-nonspecific alkaline phosphatase (TNSALP) activity, is caused by loss-of-function mutations in the ALPL gene, which encodes TNSALP. The most frequent pathogenic variant in J
Externí odkaz:
https://doaj.org/article/f78e672c32c642a5a0fb2b749ea16077
Autor:
Kenichi Mishima, Atsushi Fujita, Seiji Mizuno, Masaki Matsushita, Tadashi Nagata, Yasunari Kamiya, Noriko Miyake, Naomichi Matsumoto, Shiro Imagama, Hiroshi Kitoh
Publikováno v:
Clinical Case Reports, Vol 8, Iss 12, Pp 3109-3114 (2020)
Abstract This article reports a girl with Bardet‐Biedl syndrome (BBS) having a novel causative mutation who developed Legg‐Calvé‐Perthes disease (LCPD). There exists a possibility that the prognosis of LCPD had been adversely affected by the c
Externí odkaz:
https://doaj.org/article/c903355b8ee74bb685bdffe65ba9f109
Autor:
Genta Takemoto, Masaki Matsushita, Takaaki Okamoto, Toshinari Ito, Yuki Matsuura, Chieko Takashima, Toyofumi Fengshi Chen-Yoshikawa, Hiromichi Ebi, Shiro Imagama, Hiroshi Kitoh, Kinji Ohno, Yasuyuki Hosono
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2022)
Meclozine has been developed as an inhibitor of fibroblast growth factor receptor 3 (FGFR3) to treat achondroplasia (ACH). Extracellular signal regulated kinase (ERK) phosphorylation was attenuated by meclozine in FGF2-treated chondrocyte cell line,
Externí odkaz:
https://doaj.org/article/c34b8201d58b4d52b95eea27a34b8859
Autor:
Shinya Kaneko, Masaki Matsushita, Kenichi Mishima, Yasuhiko Takegami, Shiro Imagama, Hiroshi Kitoh
Publikováno v:
Bone Reports, Vol 13, Iss , Pp 100708- (2020)
Achondroplasia (ACH) is the most common form of short-limbed skeletal dysplasia. Patients with ACH sometimes undergo lower limb lengthening to get functional and psychological achievements. The periosteal resection (PR) is a known mechanism to increa
Externí odkaz:
https://doaj.org/article/a2bcd54bc5a541f09ae29b254ffd2813
Autor:
Tadashi Nagata, Masaki Matsushita, Kenichi Mishima, Yasunari Kamiya, Kohji Kato, Miho Toyama, Tomoo Ogi, Naoki Ishiguro, Hiroshi Kitoh
Publikováno v:
Molecular Genetics & Genomic Medicine, Vol 8, Iss 3, Pp n/a-n/a (2020)
Abstract Background Achondroplasia (ACH), the most common form of short‐limbed skeletal dysplasia, is caused by gain‐of‐function mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. More than 97% of patients result from a heterozy
Externí odkaz:
https://doaj.org/article/6c57499fa41845d598302f1439131a92
Autor:
Hiroshi Kitoh, Masaki Matsushita, Kenichi Mishima, Tadashi Nagata, Yasunari Kamiya, Kohei Ueda, Yachiyo Kuwatsuka, Hiroshi Morikawa, Yasuhiro Nakai, Naoki Ishiguro
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0229639 (2020)
Achondroplasia (ACH) is the most common short-limbed skeletal dysplasia caused by activating mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. We identified that meclizine hydrochloride inhibited FGFR3 signaling in various chondrocyt
Externí odkaz:
https://doaj.org/article/dfebcf488aa544068e1bb6e42e213aed
Autor:
Hiroshi Mano, Sayaka Fujiwara, Kazuyuki Takamura, Hiroshi Kitoh, Shinichiro Takayama, Tsutomu Ogata, Shuji Hashimoto, Nobuhiko Haga
Publikováno v:
BMC Musculoskeletal Disorders, Vol 19, Iss 1, Pp 1-10 (2018)
Abstract Background Congenital limb deficiency is a rare and intractable disease, which impairs both function and appearance of the limbs. To establish adequate medical care, it is necessary to reveal the actual conditions and problems associated wit
Externí odkaz:
https://doaj.org/article/4c3f5dd9b46945eaaee8adbe715d6afe
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Achondroplasia (ACH) is the most common short-limbed skeletal dysplasia caused by gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3). No effective FGFR3-targeted therapies for ACH are currently available. By drug r
Externí odkaz:
https://doaj.org/article/d105b8f11c35482fbfa7a96465102627